Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study

Transplant Infectious Disease

Volumn 18, Issue 3, 2016, Pages 390-395

  Young, P G ^a   Rubin, J ^b   Angarone, M ^c   Flaherty, J ^c   Penugonda, S ^c   Stosor, V ^c   Ison, M G ^c  

^a CHRIST HOSPITAL   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

abdominal transplant; cytomegalovirus; ganciclovir resistance; solid organ transplant

Indexed keywords

ALEMTUZUMAB; FOSCARNET; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GENOTYPE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS RESISTANCE;

EID: 84973861545     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12537     Document Type: Article

References (16)

1. San Juan R, Aguado JM, Lumbreras C, et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008; 47 (7): 875–882.
2. Torres-Madriz G, Boucher HW. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2008; 47 (5): 702–711.
3. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143 (12): 870–880.
4. Hodson EM, Craig JC, Strippoli GF, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008; 2: Cd003774.
5. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43 (7): 869–880.
6. Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant 2013; 13 (Suppl 3): 24–40; quiz 40.
7. Myhre HA, Haug Dorenberg D, Kristiansen KI, et al. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation 2011; 92 (2): 217–223.
8. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23 (4): 689–712.
9. Chou S. Approach to drug-resistant cytomegalovirus in transplant recipients. Curr Opin Infect Dis 2015; 28 (4): 293–299.
10. Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189 (9): 1615–1618.
11. Boivin G, Goyette N, Farhan M, Ives J, Elston R. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol 2012; 53 (3): 208–213.
12. Minces LR, Nguyen MH, Mitsani D, et al. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrob Agents Chemother 2014; 58 (1): 128–135.
13. Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83 (3): 298–304.
14. Walker JK, Scholz LM, Scheetz MH, et al. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. Transplantation 2007; 83 (7): 874–882.
15. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction – long-term results. Am J Transplant 2005; 5 (10): 2539–2548.
16. Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis. Transpl Infect Dis 2015; 17 (2): 163–173.